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Abstract
Background: The Global Programme to Eliminate Lymphatic Filariasis recommends the transmission assessment
survey (TAS) as the preferred methodology for determining whether mass drug administration can be stopped in
an endemic area. Because of the limited experience available globally with the use of Brugia Rapid™ tests in
conducting TAS in Brugia spp. areas, we explored the relationship between the antibody test results and
Brugia spp. infection as detected by microfilaremia in different epidemiological settings.
Methods: The study analyzes the Brugia Rapid™ antibody responses and microfilaremia in all ages at three study
sites in: i) a district which was classified as non-endemic, ii) a district which passed TAS, and iii) a district which
failed TAS. Convenience sampling was done in each site, in one to three purposefully selected villages with a
goal of 500 samples in each district.
Results: A total of 1543 samples were collected from residents in all three study sites. In the site which was classified
as non-endemic and where MDA had not been conducted, 5 % of study participants were antibody positive, none was
positive for microfilaremia, and age-specific antibody prevalence peaked at almost 8 % in the 25–34 year-old age
range, with no antibody-positive results found in children under eight years of age. In the site that had passed
TAS, 1 % of participants were antibody positive and none was positive for microfilaremia. In the site which failed
TAS, 15 % of participants were antibody positive, 0.2 % were microfilaremic, and age-specific antibody prevalence
was highest in 6–7 year olds (30 %), but above 8 % in all age levels above 8 years old.
Conclusions: These results from districts which followed the current WHO guidance for mapping, MDA, and
implementing TAS, while providing antibody profiles of treated and untreated populations under programmatic
settings, support the choice of antibody prevalence in the 6- and 7-year-old age group in TAS for making stopping
MDA decisions. Since only one study participant was microfilaremic, no conclusions could be drawn about
the relationship between antibodies and microfilaremia and further longitudinal studies are required to
understand this relationship.
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Lymphatic filariasis (LF), also known as elephantiasis, is a
parasitic disease caused by three species of parasitic
worms – Wuchereria bancrofti, Brugia malayi, and Brugia
timori – and transmitted by mosquitoes. It can cause clin-
ical complications of lymphedema and hydrocele, making
it one of the most disabling diseases in the world. LF is en-
demic in 73 countries, with 57 % of the at-risk population
living in the World Health Organization (WHO)’s Southx-
East Asia Region, which includes three of the largest en-
demic countries - India, Bangladesh and Indonesia [1].
In 1997, the World Health Assembly passed resolution
50.29, calling for the elimination of LF as a public-health
problem [2]. The strategy for interrupting transmission
of LF includes the sequential activities of mapping, mass
drug administration (MDA), post-MDA surveillance and
validation. In 2011, WHO published updated monitoring
and evaluation guidance, based on operational research
conducted mostly in W. bancrofti areas [3, 4]. This guid-
ance introduced the transmission assessment survey
(TAS), an impact survey designed to determine whether
prevalence has been lowered to such a level that MDA
could be stopped and recrudescence would not occur.
This infection level is likely to be reached after five to
six annual MDA rounds with effective coverage of at
least 65 % of the total population. The TAS uses a
population-based cluster-sampling methodology to esti-
mate prevalence among 6–7 year old children in an
evaluation unit.
Evaluation units ‘pass’ TAS if the number of positive chil-
dren are equal to or below a defined threshold (the ‘critical
cut off ’), determined by the size of the population and pow-
ered so that the evaluation unit has at least a 75 % chance
of passing if the true prevalence is half the critical threshold
level (defined as 2 % in areas where Culex, Anopheles, and
Mansonia are the mosquito species serving as the vectors
of the infection) [3].
InW. bancrofti areas, prevalence is measured using anti-
gen, detected using a point-of-care test, the immunochro-
matographic test. An antigen detection test is preferred
for measuring prevalence during TAS as it is more sensi-
tive to detection than microfilaremia and can be measured
using a rapid test at any time of day, while measurement
of microfilaremia requires laboratory tests, usually with
blood collected in late evenings [5].
For Brugia spp. infections, however, there is no antigen-
detection test, so WHO recommends the use of the
Brugia Rapid™ antibody-detection test [Reszon Diagnostics
International, Subang Java, Selangor, Malaysia] in Brugia
spp. areas. The Brugia Rapid™ test uses a recombinant
B. malayi antigen BmR1 and has been previously eval-
uated for sensitivity and specificity [6, 7]. Antibody
testing is useful in evaluating programmatic endpoints
as antibodies are more sensitive than microfilaremia
or antigenaemia and develop earlier in the course of
the infection [8–10].
Although “critical cut off” thresholds identical to those in
W. bancrofti areas are used, experience with these thresh-
olds for antibody prevalence in the Brugia spp. areas is, un-
fortunately, very limited. WHO TAS guidance, while
recognizing that these thresholds might be conservative, as
antibody levels are most likely to be higher than antigen
levels, suggested operational research to better understand
the “precise relationship between antibody prevalence in
children and sustainability of transmission” [3]. The
present study, conducted under programmatic conditions,
profiles a descriptive analysis of the Brugia Rapid™ antibody
responses and microfilaremia in both children and adults
in communities being assessed for their non-endemic or
post-MDA LF status to better understand this relationship.
Indonesia context
Indonesia has one of the heaviest burdens of LF globally,
spread throughout 241 districts, with 86 million people at
risk. LF in Indonesia is caused by all three parasites and
transmitted by a variety of mosquito vectors. MDA using
diethylcarbamazine citrate (DEC) (6 mg/kg) and albenda-
zole (400 mg) has been funded and implemented by district
governments, with supervision from provincial health of-
fices or the central LF team. The national LF program’s
strategy recommends annual population registration by
kaders (community health volunteers), directly-observed
treatment at MDA posts by health staff and kaders, and
door-to-door sweeping at the conclusion of the campaign.
In 2012, TAS were implemented following new WHO guid-
ance in 14 districts throughout Indonesia to determine
whether or not prevalence had fallen to levels such that
MDA could be confidently stopped.
Methods
Because of the limited experience available globally with
the use of Brugia Rapid™ tests in conducting TAS in
Brugia spp. areas it was especially important to the
Indonesia LF program to explore the relationship between
the antibody test results and Brugia spp. infection as
detected by microfilaremia. Therefore, such comparisons
were explored in three study sites: i) in all ages in a district
which was classified as non-endemic, ii) in all ages in a
district which passed TAS, and iii) in all ages in a district
which failed TAS.
Study area
One to three communities were purposively selected in
each study site. All study sites had records of B. malayi
found in blood slides in earlier studies, with no record of
people found withW. bancrofti. MDA was started in study
sites classified as endemic, i.e., those with baseline
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microfilaremia prevalence ≥1 %. The study site that had
been classified as non-endemic and where MDA had not
been conducted, Payakumbuh district in Sumatra Barat
province, had a baseline microfilaremia prevalence of 0.0 %
(0/600) in 2012. In this study site, one community was
selected after discussion with the district health office based
on highest potential risk of LF transmission. Without
known clinical cases in the district, the community was
chosen because of its proximity to and migration between
villages with chronic cases in a neighboring LF-endemic
district.
The second site, Enrekang district in Sulawesi Selatan
province, with a baseline microfilaremia prevalence of
1.06 % (4/377) in 2006, passed TAS after five rounds of ef-
fective MDA. MDA rounds were implemented between
2007 and 2011, with the reported coverage of the total
population ranging from 70 to 100 %. In 2011, sentinel and
spot-check sites found 0 % microfilaremia in 500 and 400
samples, respectively. During TAS in 2012, only one
antibody-positive result was found from a total of 1540
first- and second-grade children. Therefore, the TAS
passed and Enrekang stopped MDA. In Enrekang, two
communities were selected for this study – one with the
antibody-positive student from the 2012 TAS and one that
had positive microfilaremia results from a previous survey.
The district which failed TAS, Pasaman Barat in
Sumatra Barat province, had a baseline microfilaremia
prevalence of 18.5 % (61/330) in one site in 2002. MDA
was implemented on a sub-district basis from 2004 to
2010, with reported coverage rates ranging from 47 to
95 % of the total district population and all sub-districts
reporting taking part in five rounds. TAS was undertaken
in 2012 after assessments in 2010 in sentinel and spot-
check sites found 0.0 % (0/539) and 0.5 % (2/383) microfi-
laremia, respectively. During TAS, 64 antibody-positive
results were found from a total of 1353 first- and sec-
ond-grade children. The three selected communities in
Pasaman Barat were those villages with antibody-positive
students from the school with the most positive Brugia
Rapid™ test results from the 2012 TAS.
Sample collection
Two-person research teams from the National Institutes
of Health Research and Development (NIHRD) in Jakarta,
the section of the Ministry of Health of Indonesia respon-
sible for implementing health research, accompanied
Ministry of Health national LF elimination program staff
to the communities to collect samples in September 2013.
Convenience sampling was done in each community, with
a goal of 500 samples in each community from resi-
dents ≥5 years of age. Antibody and microfilaremia testing
was done on all participants. Data – including name, age,
sex, and address – was collected on paper forms. The
village head and health volunteers announced the survey
to the community before the research team arrived and
every individual who agreed to participate was tested.
Blood tests
For microfilaremia testing, 60 microliters of finger prick
blood was taken between the hours of 10 pm and 2 am,
drawn into three lines on a slide, and stained with Giemsa
in the field after 24 h. NIHRD staff in the field and in
Jakarta read the slides. Ten percent of negative slides and
all positive results were cross-checked by the lead NIHRD
team member. Health center staff were informed of the
microfilaremia positive results so they could follow up with
treatment with albendazole and DEC. Blood was taken for
antibody testing at the same time as blood was taken for
microfilaremia testing. Antibody positivity was assessed by
the Brugia Rapid™ cassette test, following test instructions,
scoring positive, negative or ‘invalid’ due to lack of positive
control line on the test, blood not flowing up or clearing
from the strip, or insufficient blood applied to the test.
Thirty-five microliters of whole blood from finger prick
was tested, with tests read visually at 25 min.
Analysis
Data was entered into Excel by NIHRD staff. Analysis was
done in Excel to determine breakdown of age, gender,
antibody-positivity and microfilaremia in each district.
Age-specific antibody prevalence also was calculated for
each study site.
Ethics statement
Ethical approval was given by the Indonesia Institutional
Review Board. Informed consent was given in commu-
nity surveys by the head of village, as is typical practice
by NIHRD.
Results
A total of 1543 samples were collected from residents in
all three study sites. The median age in the study sites
ranged from 21 years to 33 years. Overall demographic
results from the study are presented in Table 1.
Non-endemic site
In Payakumbuh, a total of 23 (5 %) study participants
were antibody positive; however, none was positive for
microfilaremia. Almost 6 % of females and 3 % of males
were antibody positive (Table 2). Age-specific antibody
prevalence peaked at almost 8 % in the 25–34 year-old
age range, with no antibody-positive results found in
children under eight years of age (Fig. 1).
Post-MDA, passing TAS site
Results from Enrekang district showed three (1 %)
participants were antibody positive, 21 (4 %) had invalid
Brugia Rapid™ tests, and 490 (95 %) were antibody
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negative. Invalid tests were not repeated due to lack of
extra Brugia Rapid™ tests. All 514 participants were
negative for microfilaremia. The results are shown in
Fig. 1.
Post-MDA, failing TAS site
In our study, 79 (15 %) of participants in Pasaman Barat
were antibody positive, one (0.2 %) had an invalid Brugia
Rapid™ test, and 443 (85 %) were antibody negative. Over-
all almost 65 % of participants were female; however, 33 %
of 6- and 7-year-olds and 51 % of 8- to 14-year-olds were
female. One participant, a 22-year-old male, was positive
for B. malayi microfilaremia (as well as antibodies). Age-
specific antibody prevalence was highest in 6–7 year
olds (30 %), although this was a small sample, with only
33 (6.3 %) of total participants included in this age
range. Prevalence was above 8 % in all age levels above
8 years old (Fig. 1).
Discussion
A better understanding of antibody responses in all ages is
critical for determining the appropriateness of current
WHO guidelines in Brugia spp. areas. Our study found
antibody results in all ages consistent with the outcomes of
the previous mapping and TAS activities. The district which
failed TAS (Pasaman Barat) had the highest antibody preva-
lence of the three study sites. In contrast, in the district
which passed TAS (Enrekang), only a few antibody-positive
individuals were identified. While a higher number of in-
valid tests were reported in Enrekang, two of these were in
the 6- and 7-year-old age group. Even if these children ac-
tually were antibody positive, it would still be markedly
lower in Enrekang (5 %) than in Pasaman Barat (30 %).
While antibody-positive individuals were found in the
district originally classified as non-endemic based on
microfilaremia prevalence (Payakumbuh), overall anti-
body prevalence in this study site was low. The overall
antibody prevalence in Enrekang (the district that passed
TAS) was the lowest among all the three districts stud-
ied. These low levels are the consequence of successful
implementation of effective MDA that reduced exposure
to the parasite. The next highest levels seen in Payakumbuh
(the non-endemic district), reflect low level exposure to the
parasite (possibly from neighboring endemic districts) since
no interventions were undertaken in this area. The Ministry
of Health LF elimination program’s surveillance activities
require monitoring of non-endemic districts, which will
help to identify if interventions are needed in the future.
The TAS guidance recommends using a survey popula-
tion of 6- and 7-year-olds because “they should be pro-
tected from LF infection if the MDAs have been successful
in interrupting transmission. Antigenemia in young chil-
dren is a marker for relatively recent events of transmis-
sion, while antigenemia in older children or adults may be
related to infections that occurred before MDA” [3]. How
applicable the 6- and 7-year-old age group is when anti-
body diagnostics are used is still a matter of some debate.
A multicenter evaluation of diagnostic tools in W. bancrofti
areas after five years of MDA found antibody reactivity to
the recombinant antigen Bm14 to be similar among all age
groups: 30 % (0–5 years), 32 % (6–10 years), and 37 % (all
ages) [5]. Similarly, research in the Cook Islands found that
Wb123 antibody prevalence in children did reflect W. ban-
crofti infection and transmission in the overall population
[11]. Not surprisingly, antibody prevalence before treat-
ment in Papua New Guinea, measured by IgG4 antibodies
to Bm14 detected by ELISA, was higher in adults (59.3 %)
Table 2 LF antibody positivity, by site and age group
District Category Number (%) of
antibody-positive
participants
Number (%) of antibody-positive participants, by age range (in years) Number (%) of antibody-
positive participants, by sex
≤5 6–7 8–14 15–24 25–34 35–44 45–54 ≥55 Female Male
Payakumbuh Non-
endemic
23 (5) 0 (0) 0 (0) 5 (5.2) 2 (2.7) 6 (7.9) 3 (3.3) 4 (5.0) 3 (4.7) 15 (5.7) 8 (3.3)
Enrekang Pass TAS 3 (1) 0 (0) 0 (0) 1 (0.7) 1 (1.9) 0 (0) 0 (0) 0 (0) 1 (1.5) 2 (0.9) 1 (0.4)
Pasaman Barat Fail TAS 79 (15) 0 (0) 10 (30.3) 26 (15.4) 9 (12.9) 13 (17.8) 12 (12.9) 5 (8.6) 4 (16.7) 47 (14.0) 32 (17.2)





Number (%) of participants by age range (in years) Number (%) of
participants by sex
≤5 6–7 8–14 15–24 25–34 35–44 45–54 ≥55 Female Male
Payakumbuh Non-
endemic
506 33 3 (0.6) 21 (4.2) 96 (19.0) 74 (14.6) 76 (15.0) 92 (18.2) 80 (15.8) 64 (12.6) 261 (51.6) 245 (48.4)
Enrekang Pass TAS 514 27 16 (3.1) 37 (7.2) 139 (27.1) 53 (10.3) 53 (10.3) 80 (15.6) 70 (13.6) 65 (12.7) 232 (45.1) 282 (54.9)
Pasaman
Barat
Fail TAS 523 21 3 (0.6) 33 (6.3) 169 (32.3) 70 (13.4) 73 (14.0) 93 (17.8) 58 (11.1) 24 (4.6) 335 (64.3) 186 (35.7)
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than in children 6- to 10-years-old (35.8 %). In addition,
after three rounds of MDA, antibody prevalence decreased
faster in children less than 11 years of age than in
the total population; perhaps due to lower infection
intensity or shorter duration of infection in the chil-
dren than in adults [12].
Previous studies which examined antibody prevalence in
Brugia spp. areas found that antibody levels in children
(defined as under 15 or under 10 years old) were similar
to levels in adults in pretreatment situations [6, 13, 14].
However, there is limited information on the age-specific
prevalence of antibody in post-treatment Brugia spp.
areas – in particular, in areas that had conducted mass drug
administration and not individual treatment. Supali, et al.,
using a dipstick version of the Brugia Rapid™ test, showed
a decrease in antibody prevalence from 80 % pretreatment
to 6.4 % post-MDA in Alor Island, Indonesia after six
rounds of MDA [15]. A study in Sarawak, Malaysia that
used Brugia Rapid™ cassette tests found baseline rates of
70 % antibody prevalence among all ages, which fell
to 3.5 % after three years of treatment [7]. The authors re-
ported a non-significant difference between post-MDA
antibody levels in individuals less than 21 years of
age (4.9 %) and in adults (8.7 %).
The relationship between antibody positivity and micro-
filaremia has been examined in only a few studies so far.
While antibody tests detected 10 times and 50 % more
antibody-positive individuals than microfilaremic individ-
uals (by thick smear examination) in studies reported by
Jamail [14] and Noordin [7] respectively, the antibody to
microfilaremia ratio was 3:1 in a study by Supali [15]. The
relationship between antibody positivity and microfilaremia
could not be analyzed in our study because only one
microfilaremic individual was found in all three study sites.
The low level of microfilaremia in all the three sites suggest
that infections are still light (even in Pasaman Barat) since
antibody is known to be detected earlier and with greater
sensitivity than antigenemia or microfilaremia [13].
Conclusions
The results of our study have important messages for MDA
programs in Brugia spp. areas, particularly because the
study was conducted under programmatic conditions ac-
cording to WHO guidelines for mapping and stopping
MDA. In the TAS-failing Pasaman Barat district, although
fewer individuals were tested in the 6- and 7-year-old age
group, 30.3 % of them were antibody positive, a level even
higher than those in all other age groups (8.6 % to 17.8 %).
The antibody findings in the older age groups are consist-
ent with infection having occurred in the past, while the re-
sults in 6- and 7-year-olds (born after the start of MDA in
2004) agree with the TAS result suggesting that transmis-
sion is still ongoing and that MDA should be continued.
Conversely, in Enrekang and Payakumbuh, the results
in all ages appear to indicate that these areas have
minimal, if any, ongoing transmission and do not need
MDA. Notably, this conclusion could be drawn from
the results in 6- and 7-year-olds only in these two study
sites. Taken together, these observations strongly sup-
port the current WHO recommended strategy of using
antibody levels in the 6-and 7-year-old age group for
stopping MDA based on TAS.
Clearly, further follow up is required not only to as-
sess the antibody profile in these communities but also
the effect of interventions in the long term. Longitu-
dinal collection of data planned by the Indonesian
national LF elimination program includes follow up of
antibody levels in Pasaman Barat after two more rounds
of MDA. Similarly, it would be important to include
Payakumbuh in ongoing LF surveillance since the
antibody-positivity levels are suggestive of transmission
in the past and migration to Payakumbuh from known
endemic districts is known to exist. Such a strategy will
help in early identification of infection of levels that
require institution of MDA in the district.
While the results of our study provide epidemiological
support for the use of antibody levels to determine
Fig. 1 Age-specific prevalence for LF antibody, by study site
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“critical cut-off thresholds” in Brugia spp. areas, further
comprehensive studies using population-based surveys
will undoubtedly contribute significantly to our growing
understanding of antibody positivity and its practical
usefulness at all stages of the LF program.
Abbreviations
DEC: Diethylcarbamazine citrate; LF: Lymphatic filariasis; MDA: Mass drug
administration; NIHRD: National Institute for Health Research and
Development; TAS: Transmission assessment survey; WHO: World Health
Organization.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
Study design: RMD, CA, RL, HH, SG, MB. Data collection: RMD, ST, EA, RL.
Study analysis: RMD, MB. Writing: MB. All authors read and approved the final
version of the manuscript.
Acknowledgements
The authors would like to thank the study participants and the NIHRD
laboratory team. The authors would also like to thank Patrick Lammie, Eric
Ottesen, and V. Kumaraswami for feedback on early manuscript drafts.
Financial support: This work was made possible thanks to the generous
support of the American People through the United States Agency for
International Development and the ENVISION project led by RTI International.
The authors’ views expressed in this publication do not necessarily reflect
the views of the United States Agency for International Development or the
United States Government.
Author details
1National Institute of Health Research and Development, Indonesia Ministry
of Health, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia.
2Sub-Directorate of Filariasis & Helminthiasis Control, Directorate of Vector
Borne Disease Control, Directorate General of Communicable Disease and
Environmental Health, Indonesia Ministry of Health, Jl. Percetakan Negara No.
29, Jakarta 10560, Indonesia. 3RTI International-Indonesia, Menara Thamrin,
15th Floor, Suite 1503, Jl. M.H. Thamrin Kav. 3, Jakarta 10250, Indonesia. 4RTI
International, 701 13th Street NW, Suite 750, Washington, DC 20008, USA.
Received: 28 April 2015 Accepted: 15 September 2015
References
1. World Health Organization. Global programme to eliminate lymphatic
filariasis: progress report, 2013. Wkly Epidemiol Rec. 2014;89:409–20.
2. World Health Assembly. World Health Assembly Resolution 50.29.
Geneva; 1997.
3. World Health Organization. Global programme to eliminate lymphatic
filariasis: monitoring and epidemiological assessment of mass drug
administration. Geneva: World Health; 2011.
4. Chu BK, Deming M, Biritwum N-K, Bougma WR, Dorkenoo AM, El-Setouhy M, et al.
Transmission assessment surveys (TAS) to define endpoints for lymphatic
filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop
Dis. 2013;7, e2584. doi:10.1371/journal.pntd.0002584.
5. Gass K, de Rochars MVE B, Boakye D, Bradley M, Fischer PU, Gyapong J,
et al. A multicenter evaluation of diagnostic tools to define endpoints for
programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis.
2012;6:e1479. doi:10.1371/journal.pntd.0001479.
6. Rahmah N, Shenoy RK, Nutman TB, Weiss N, Gilmour K, Maizels RM, et al.
Multicentre laboratory evaluation of Brugia Rapid dipstick test for detection
of brugian filariasis. Trop Med Int Health. 2003;8:895–900. Available:
http://www.ncbi.nlm.nih.gov/pubmed/14516300.
7. Noordin R, Muhi J, Md Idris Z, Arifin N, Kiyu A. Duration of detection of
anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in
Sarawak, Malaysia. Trop Biomed. 2012;29:191–6. Available:
http://www.ncbi.nlm.nih.gov/pubmed/22543621.
8. Lammie PJ, Weil G, Noordin R, Kaliraj P, Steel C, Goodman D, et al.
Recombinant antigen-based antibody assays for the diagnosis and
surveillance of lymphatic filariasis – a multicenter trial. Filaria J. 2004;3:9.
doi:10.1186/1475-2883-3-9.
9. Weil GJ, Ramzy RMR. Diagnostic tools for filariasis elimination programs.
Trends Parasitol. 2007;23:78–82. doi:10.1016/j.pt.2006.12.001.
10. Hamlin KL, Moss DM, Priest JW, Roberts J, Kubofcik J, Gass K, et al.
Longitudinal monitoring of the development of antifilarial antibodies and
acquisition of Wuchereria bancrofti in a highly endemic area of Haiti. PLoS
Negl Trop Dis. 2012;6, e1941. doi:10.1371/journal.pntd.0001941.
11. Steel C, Kubofcik J, Ottesen EA, Nutman TB. Antibody to the Filarial Antigen
Wb123 reflects reduced transmission and decreased exposure in children
born following single Mass Drug Administration (MDA). PLoS Negl Trop Dis.
2012;6:1–8. doi:10.1371/journal.pntd.0001940.
12. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, King CL, et al. The
impact of repeated rounds of mass drug administration with
diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New
Guinea. Test. 2008;2:e344. doi:10.1371/journal.pntd.0000344.
13. Supali T, Rahmah N, Djuardi Y, Sartono E, Rückert P, Fischer P. Detection of
filaria-specific IgG4 antibodies using Brugia Rapid test in individuals from an
area highly endemic for Brugia timori. Acta Trop. 2004;90:255–61.
doi:10.1016/j.actatropica.2004.02.001.
14. Jamail M, Andrew K, Junaidi D, Krishnan AK, Faizal M, Rahmah N. Field
validation of sensitivity and specificity of rapid test for detection of
Brugia malayi infection. Trop Med Int Health. 2005;10:99–104.
doi:10.1111/j.1365-3156.2004.01334.x.
15. Supali T, Djuardi Y, Bradley M, Noordin R, Rückert P, Fischer PU. Impact
of six rounds of mass drug administration on Brugian Filariasis and
Soil-Transmitted Helminth Infections in Eastern Indonesia. PLoS Negl
Trop Dis. 2013;7:1–9. doi:10.1371/journal.pntd.0002586.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dewi et al. Parasites & Vectors  (2015) 8:499 Page 6 of 6
